Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuwellis Inc (NUWE) vs Rocket Lab USA Inc (RKLB) Price & Performance

Nuwellis IncTrade
Rocket Lab USA IncTrade

Price performance (Past 24H)

Key statistics

Nuwellis Inc vs Rocket Lab USA Inc — how do they compare? Nuwellis Inc trades at $1.41 (market cap $542.80K), while Rocket Lab USA Inc trades at $81.08 (market cap $50.01B). The key difference: Rocket Lab USA Inc is far larger — about 92133.4× Nuwellis Inc's market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

NUWERKLB
Market Cap
$542.80K$50.01B
Sector
TechnologyTechnology
52-Week High
$220.50$150.23
52-Week Low
$1.42$39.48
Enterprise Value
-$1.27M$47.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuwellis Inc

NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.

The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $81.30, up 1.57% in the last session, with a bullish technical outlook and strong analyst support. The stock is near its pivot point of $79, with resistance at $82. Fundamentally, revenue grew 62% year-over-year in Q2 2026 to a record $601.80 million, but the company remains unprofitable with a net income margin of -26.87%. Recent news highlights the Neutron rocket's upcoming launch and a $2.36 billion backlog, though margin pressures and cash burn are concerns.

The outlook is mixed: analysts project 76% buy ratings and a $118.00 price target, signaling confidence in growth from launch demand and contracts. However, high valuation (P/S of 60.8), persistent losses, and execution risks around Neutron's timeline pose significant downside. Investors should weigh growth potential against profitability challenges and competitive pressures in the space sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB